Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

January 11, 2022 by Alan Khadavi

New Food Allergy Treatments

New food allergy treatments are on the horizon, notably for biologic medications. Multiple studies are underway evaluating whether biologic medications can help increase the amount patients with food allergy can consume before having an allergic reaction. Other studies are evaluating biological therapy with oral immunotherapy (OIT).

Xolair and Ligelizumab

There have been several studies with Xolair evaluating its ability to allow patients to have a higher threshold for reactivity to an offending food. Studies with peanut have found an increase in the tolerated peanut dose, but severe reactions were seen along the way. However 1 study reported an increase from 80 mg to 10,000 mg (35 peanut kernels) after 6 months. Other studies showed an 8 fold increase in milk, egg, wheat and hazelnuts with Xolair. There is a current study called the omalizumab as monotherapy and as adjunct therapy to multi-allergen OIT in food allergic participants (OUtMATCH).

As described previously, ligelizumab seems to have a better ability to block mast cells and basophil mediated events than Omalizumab (Xolair).

Dupilumab

There are no current published studies for Dupixent and food allergy, but studies are underway. Most are to evaluate if the dose threshold eliciting is increased. Dupixent and OIT studies are looking at peanut and another with milk.

Etokimab

Etokimab is an anti-IL 33 monoclonal that was evaluated in 20 patients with peanut allergy. After 1 dose, 73% passed a 275 mg challenge after 2 weeks. More studies for Etokimab will need to be done to evaluate whether this is a safe long term option for patients.

New food allergy treatments are currently being developed and it is very exciting for the millions of patients who have food allergies. Its too soon to say if any of these treatments will get FDA approval in the future. It will be difficult to predict the biologics role as either monotherapy or in conjunction with immunotherapy.

There are currently about 32 million Americans who have food allergies and the health care system could not support all of these patients on expensive biologic medications.

 

 

 

Filed Under: Blog, Food allergy

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page